Skip to content
Menu

Legend Biotech Corporation LEGN

Full chart Compare
Set alert

Price alert · LEGN

All alert types
17.50 USD -1.04 (-5.61%)

Regular-session close

17.20 -0.30 -1.71%

Pre-market · Nov 16, 7:46 AM ET

17.39 Day range 18.61
16.24 52-week range 37.50
YTD
-19.50%
1 year
-43.57%
Market cap
3.39B
Revenue (ttm)
1.36B
Profit margin
-0.01%
EPS (ttm)
-0.02
Shares out
193.97M
Forward P/E
20.73
YTD return
-19.50%
1-year return
-43.57%
Volume
3.03M
Avg volume
2.23M
Open
18.46
Previous close
18.54
Day's range
17.39 – 18.61
52-week range
16.24 – 37.50
Beta
0.55
Analysts
Buy
Price target
42.46 (+142.6%)
Earnings date
Mar 9, 2027

5D -5.50 (-23.91%)

17.502022.50MonTueWedThuFri17.50

Key statistics

Enterprise value
2.91B
PEG ratio
0.00
Price / sales
2.50
Price / book
2.67
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
32.00%
Free cash flow
-21.17M
Total cash
852.50M
Total debt
167.40M
Return on equity
-0.02%
Short % of float
14.56%
50-day average
19.66
200-day average
22.19

Fundamental scorecard

9 of 25 checks passed on LEGN’s reported financials

Value: 2/5ValueGrowth: 3/5GrowthProfitability: 1/5ProfitabilityFinancial health: 3/5HealthDividend: n/aDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
LEGN Revenue — quarterly 359.50M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
LEGN Net income — quarterly 51.70M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
LEGN EPS — quarterly 0.26
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

LEGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 9, 2027Mar 30, 20270.05———
Nov 10, 2026Sep 30, 20260.010.14+0.13+1,300.00%
Aug 11, 2026Jun 30, 20260.120.09-0.03-25.00%
May 12, 2026Mar 31, 2026-0.02-0.15-0.13-650.00%
Mar 10, 2026Dec 31, 2025-0.17-0.08+0.09+52.94%
Nov 12, 2025Sep 30, 2025-0.13-0.11+0.02+15.38%

Upgrades / downgrades

LEGN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026OppenheimermainPerformPerform
Nov 11, 2026Morgan StanleymainOverweightOverweight
Nov 11, 2026BarclaysmainOverweightOverweight
Nov 11, 2026RBC CapitalmainOutperformOutperform
Oct 13, 2026BarclaysmainOverweightOverweight
Oct 9, 2026JP MorganmainNeutralNeutral

About Legend Biotech Corporation

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on LEGN — it syncs with the Stock Master app.

Insider holders

LEGN insider holders
InsiderRelationLatest transactionDateShares held
BASH ALANChief Executive OfficerStock Award(Grant)Aug 13, 202635,142
CASEY PATRICK JOHN PH.D.DirectorStock Award(Grant)Sep 23, 202669,590
HEYMAN TOMAS J.DirectorStock Award(Grant)Sep 23, 202653,720
HUANG YINGChief Executive OfficerStock GiftJun 29, 2026238,490
JI DARREN XIAOHUIDirectorStock Award(Grant)Sep 23, 202692,103
MAO LIDirectorStock Award(Grant)Sep 23, 202665,316

Institution ownership

LEGN institution ownership
Holder% heldSharesValueReported
FMR, LLC12.49%24,197,404423.45MSep 29, 2026
Deerfield Management Company, L.P4.20%8,137,638142.41MJun 29, 2026
Montanova Capital LLC3.65%7,070,000123.72MJun 29, 2026
HHLR Advisors, LTD3.09%5,984,550104.73MJun 29, 2026
Westfield Capital Management Co LP2.66%5,150,14690.13MSep 29, 2026
Blackrock Inc.2.44%4,726,53482.71MJun 29, 2026

Fund ownership

LEGN fund ownership
Holder% heldSharesValueReported
Fidelity Select Portfolios-Select Pharmaceuticals Portfolio1.34%2,591,70045.35MSep 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.31%2,530,83144.29MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.18%2,280,00039.90MSep 29, 2026
Fidelity Contrafund0.99%1,920,81833.61MSep 29, 2026
Variable Insurance Products Fund II-VIP Contrafund Portfolio0.98%1,890,19633.08MSep 29, 2026
Fidelity Investment Trust-Fidelity Emerging Markets Fund0.89%1,729,10030.26MSep 29, 2026